LabCorp Announces the Availability of a 4th Generation HIV Assay to Allow the Earlier Detection of Acute HIV Infection

  LabCorp Announces the Availability of a 4th Generation HIV Assay to Allow
  the Earlier Detection of Acute HIV Infection

Business Wire

BURLINGTON, N.C. -- November 6, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) announced
today the availability of a 4^th generation HIV antigen/antibody combination
assay and a new diagnostic algorithm that improves screening for HIV
infection.

Earlier detection of HIV can improve individual treatment and help reduce the
spread of HIV in the population. New 4^th generation HIV assays have the
ability to detect both the HIV antibodies (IgG and IgM) and the HIV p24
antigen simultaneously prior to seroconversion. On average, the 4^th
generation assay allows for detection of HIV seven days earlier in acutely
infected individuals than would be possible with 3^rd generation assays. These
assays are an important enhancement to LabCorp’s test menu, which encompasses
the most comprehensive, cost-effective diagnostic products available to
provide physicians and their patients critical information for the screening,
diagnosis and treatment of multiple disease states.

In addition to offering this advanced HIV diagnostic tool, LabCorp introduced
a new diagnostic algorithm that significantly improves the screening and
diagnosis of HIV infection. The algorithm uses the 4^th generation test as a
first step, with subsequent confirmation of the initial HIV-positive result
with a highly sensitive and specific immunoassay that is FDA approved to
differentiate between HIV-1 and HIV-2 infections. Inconsistent findings are
further resolved by nucleic acid testing to identify potential early acute
infection. The Clinical Laboratory Standards Institute (CLSI) and the New York
State Department of Health have recommended the use of this enhanced algorithm
for HIV screening and the Centers for Disease Control and Prevention (CDC) has
recently issued two positive evaluations of the new HIV diagnostic testing
algorithm on its online Morbidity and Mortality Weekly Report. The algorithm
is configured to be cost-effective for patients and payers while providing
high quality results.

“Fourth-generation HIV screening and associated supplemental testing is a
valuable addition to the tools available to achieve early diagnosis of HIV,”
said Dr. Mark Brecher, LabCorp’s Chief Medical Officer. “Detection of acute
infections using the fourth-generation assay provides an improved opportunity
for early intervention and the potential to affect transmission rates.”

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its LabCorp Specialty Testing
Group: The Center for Molecular Biology and Pathology, National Genetics
Institute, ViroMed Laboratories, Inc, The Center for Esoteric Testing,
Litholink Corporation, Integrated Genetics, Integrated Oncology, Dianon
Pathology, Monogram Biosciences, Inc, Colorado Coagulation, Cellmark
Forensics, MedTox, and Endocrine Sciences. LabCorp conducts clinical trials
testing through its LabCorp Clinical Trials division. LabCorp clients include
physicians, government agencies, managed care organizations, hospitals,
clinical labs, and pharmaceutical companies. To learn more about our
organization, visit our website at: www.labcorp.com.

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.

Contact:

Laboratory Corporation of America^® Holdings
Stephen Anderson, 336-436-5076
www.labcorp.com